
Core Insights - Cosmos Health Inc. reported solid financial results for Q1 2025, showing a significant increase in gross profit and a positive turnaround in both Adjusted EBITDA and Adjusted Net Income [2][3][9] Financial Performance - Revenue for Q1 2025 was $13.71 million, a decrease of 5.98% from $14.58 million in Q1 2024, due to a strategic shift towards higher-margin areas [6] - Gross profit increased by 53.70% to $2.05 million, up from $1.33 million in the prior-year period, driven by an improved product mix and operational leverage [6] - Adjusted EBITDA rose by 157.8% to $0.37 million, compared to a loss of $0.64 million in Q1 2024 [6] - Adjusted Net Income improved by 139.4% to $0.28 million, versus a loss of $0.71 million in the prior-year period [6] Cost Management - Total operating expenses declined by 9.05% to $2.88 million, compared to $3.17 million in Q1 2024, attributed to a 17.34% reduction in salaries and wages and an 83.78% decline in sales and marketing expenses [6] - The company achieved a net loss of $0.82 million, narrowing by 56.17% from $1.87 million in the prior-year period [6] Balance Sheet Strength - Stockholders' equity increased by $1.42 million, with a liabilities-to-assets ratio of 54.6%, indicating continued financial discipline [5][7] - Total assets rose by 5.3% to $57.2 million, while total liabilities increased by 4.9% to $31.24 million [7] Operational Developments - The wholesale logistics segment (CosmoFarm) and the owned nutraceutical and pharmaceutical products portfolio were key contributors to the improved performance [4] - The company is advancing its R&D pipeline, including the CCX0722 weight management solution, and expanding its high-margin contract manufacturing segment [11] Management Commentary - The CEO expressed satisfaction with the first-quarter performance, highlighting the significant increase in gross profit and margins, as well as the return to profitability [9][10]